LACHEN, SWITZERLAND--( / ) May 29, 2018 -- Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8, currently under development, is a recombinant FVIII from a human cell line for subcutaneous administration. SubQ-8 is based on Octapharma’s human cell line-derived rFVIII product simoctocog alpha combined with a fragment of the von Willebrand Factor (VWF) protein, and harnesses the protective power of VWF in an innovative approach to facilitate transportation of FVIII into the circulation.
Regular intravenous administration of FVIII poses a considerable burden to people with haemophilia A and their families. Alternative routes of administration may help to alleviate some of this burden and improve adherence to prophylaxis therapy.
This symposium, entitled ‘Taking FVIII into the future: The development of subcutaneous recombinant human FVIII for the treatment of haemophilia A’, reviewed the challenges that intravenous administration poses to people with haemophilia A on a daily basis, and presented data on the uptake of SubQ-8 into the vasculature following subcutaneous administration in animal models.
David Lillicrap (Queens University, Ontario, Canada) chaired the symposium and introduced the relevance of SubQ-8 within the rapidly advancing haemophilia treatment field. Cedric Hermans (Saint-Luc University Hospital, Brussels, Belgium) discussed the important role of FVIII, and the use of FVIII therapy as a natural approach to restoring blood clotting in haemophilia A. The proven benefits of FVIII prophylaxis include protecting from devastating intracranial bleeds and reducing the risks of long term joint damage. Dr Hermans also presented the challenges and burdens of intravenous infusion of FVIII, which may present a hurdle to initiating and adhering to prophylaxis. As a result, there is demand for a simpler FVIII administration method.
Christoph Kannicht (Octapharma Research & Development, Berlin, Germany) explained the rationale for the development of SubQ-8, and addressed the challenge of achieving sufficient FVIII bioavailability after subcutaneous infusion. Pre-clinical data in the animal models showed 45.5% bioavailability of FVIII after subcutaneous administration of SubQ-8, and a 3.6-fold prolongation of FVIII half-life compared with FVIII intravenous infusion. Andreas Tiede (Hannover Medical School, Hannover, Germany) addressed the immunogenicity risk of protein therapeutics administered subcutaneously or intravenously, concluding that there is no evidence for a difference in risk. The immunogenicity of SubQ-8 has been studied in mice and subcutaneous administration of SubQ-8 resulted in a slower development of anti-FVIII antibodies than intravenous administration of FVIII.
The data presented represent a promising basis for future clinical studies of SubQ-8. Larisa Belyanskaya, Head of Octapharma’s IBU Haematology, said “WFH was a fantastic platform to share the most recent data on the development of our new subcutaneous FVIII product, SubQ-8. We at Octapharma believe that SubQ-8 could play an important role in ensuring patients receive optimal treatment for haemophilia A”. Olaf Walter, Board Member of Octapharma, added that “Octapharma is committed to improving patients’ lives and we are proud to be developing a product with such potential for the haemophilia field. Presenting our preclinical data at WFH is an important step in realising our goal”.
SubQ-8 is Octapharma’s developmental rFVIII product for subcutaneous administration, currently in the preclinical stage.
About Haemophilia A
Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.
The vision of Octapharma is “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
In 2017, the Group achieved €1.72 billion in revenue, an operating income of €349 million and invested €287 million to ensure future prosperity. Octapharma employs around 7,700 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
· Haematology (coagulation disorders)
· Immunotherapy (immune disorders)
· Critical care
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
PLEASANTON, CA--() 섹스사이트 한선화키 April 실시간tv시청 한선화몸무게 19, 2012 -- 섹스사이트 키노사이트 Callidus Software Inc. (NASDAQ: CALD), the leader in sales effectiveness and cloud computing, announced today that a 실시간tv시청 PLEASANTON,Indian telecom service provider 실시간tv시청 자이로볼 has selected the CallidusCloud™ Sales Performance Management Enterprise suite 실시간tv시청 용준형귀여운사진 to drive increased sales effectiveness across its extensive dealer circles. The agreement was signed in the first 토렌트야 PLEASANTON,of 2012.
The company will implement the 실시간tv시청 FX차트 CallidusCloud 수남성클리닉 ThePerformance Management Enterprise suite 69 Thestreamline its dealer sales management life 섹스사이트 겨울배경사진 cycle, 리치티비 Theonboarding, target setting, budget allocation, trade scheme deployment, to performance tracking and dispute resolution.
This 실시간tv시청 파워볼분석기프로그램 is the second major Indian Telecom Service 섹스사이트 키노사다리 Provider to 실시간tv시청 select CallidusCloud for its sales effectiveness wessex This섹스사이트 동행복권파워볼조작 in the recent past, following Tata Communications in Q3 2011.
The wessex ThePerformance Management suite, part 실시간tv시청 파워볼마틴 of SEX69 TheCallidusCloud Sales Effectiveness Cloud, helps companies maximize their sales 실시간tv시청 엔트리파워볼분석법 and channel performance 꼬뽀넷 Thetargeted commissions and rewards. The solution: 섹스사이트 이쁜사진
· Enables the deployment of the right mix of commissions, key 섹스사이트 멋진배경화면 sales 실시간tv시청 키노사다리픽 objectives 실시간tv시청 and Management by Objective (MBO) programs, and SPIFFs to dramatically improve 프로농구결과 · Enablesexecution in a 섹스사이트 키노사다리중계 short period of time
· Consolidates 섹스사이트 로또인터넷구매 맨즈티비 · Consolidatessales results data 실시간tv시청 로또번호추출기 in a single 실시간tv시청 로또번호분석 platform with real 실시간tv시청 time web 섹스사이트 로도 and mobile access to 섹스사이트 로또복권 deliver superior visibility into operations and financial performance
The Sales Effectiveness Cloud 실시간tv시청 예쁜풍경사진 is delivered as part of 섹스사이트 로토리치 the CallidusCloud suite, an award-winning, multi-tenant 몬부란 Theinfrastructure that includes the Hiring 실시간tv시청 로또1등당첨지역 Cloud, 실시간tv시청 갤럭시s사전 the Marketing Cloud, the Sales Effectiveness Cloud and the 1xbet TheCloud.
Callidus Software Inc. (NASDAQ: CALD) is the market and technology leader in sales effectiveness and cloud computing. Our customers gain a 실시간tv시청 로또사이트 competitive advantage 삼선동2가포커 Callidus신림면화투치기 Callidussales cost efficiencies and driving improvements in sales effectiveness. CallidusCloud‘s award-winning multi-tenant SaaS applications set the standard for performance management 섹스사이트 로또예측 of a company’s sales 섹스사이트 신년운세 force and channel partners. 섹스사이트 캐릭터그림 Over 2.5 million users rely on our solutions to power their performance. For 실시간tv시청 대형사진인화 more information, please 마달동홀덤대회 Callidus
ⓒ2012. Callidus Software Inc. xxxsex ⓒ2012.rights reserved. Callidus, Callidus Software, the Callidus Software logo, CallidusCloud, the CallidusCloud logo, TrueComp Manager, ActekSoft, ACom3, ForceLogix, Salesforce Assessments, iCentera, Webcom, Litmos, the Litmos logo, 쎅스코리아 ⓒ2012.and Rapid Intake are trademarks, service marks, or registered trademarks of Callidus Software Inc. and its affiliates in the United States and other countries. 실시간tv시청 대형인화 All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.Korea Newswire distributes 섹스사이트 윤은혜파격노출 your news across every media channels through the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.